Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind
A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power
Leading experts from AIIMS Kalyani, Syngene, Veeda Lifesciences, Lambda Therapeutic, DNDi, JSS Medical, KIHT, InoRx, ISCR and SIRO Clintech to discuss India’s readiness as preferred clinical research destination
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Veteran HR leader comes with over two decades of experience to spearhead talent strategy, leadership development, and culture transformation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
